Antiviral effect of cidofovir on parvovirus B19 replication

Antiviral Research

Volumn 113, Issue , 2015, Pages 11-18

  Bonvicini, Francesca ^a   Bua, Gloria ^a   Manaresi, Elisabetta ^a   Gallinella, Giorgio ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cidofovir; Parvovirus B19; Quantitative PCR; Replication inhibition

Indexed keywords

CIDOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; CYTOSINE; PHOSPHONIC ACID DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL POPULATION; CELL PROLIFERATION ASSAY; CELL VIABILITY ASSAY; CONTROLLED STUDY; EC50; ERYTHROID PRECURSOR CELL; HOST CELL; HUMAN; HUMAN CELL; HUMAN PARVOVIRUS B19; IN VITRO STUDY; PARVOVIRUS INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; VIROLOGY;

PARVOVIRUS;

ANTIVIRAL AGENTS; BLOTTING, SOUTHERN; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYTOSINE; ERYTHROID PRECURSOR CELLS; ORGANOPHOSPHONATES; PARVOVIRUS B19, HUMAN; REAL-TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

EID: 84911932114     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.11.004     Document Type: Article

References (35)

1. E. Bernhoff, T.J. Gutteberg, K. Sandvik, H.H. Hirsch, and C.H. Rinaldo Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression Am. J. Transplant. 8 2008 1413 1422
2. F. Bonvicini, C. Filippone, S. Delbarba, E. Manaresi, M. Zerbini, M. Musiani, and G. Gallinella Parvovirus B19 genome as a single, two-state replicative and transcriptional unit Virology 347 2006 447 454
3. F. Bonvicini, C. Filippone, E. Manaresi, M. Zerbini, M. Musiani, and G. Gallinella Functional analysis and quantitative determination of the expression profile of human parvovirus B19 Virology 381 2008 168 177
4. F. Bonvicini, M. La Placa, E. Manaresi, G. Gallinella, G.A. Gentilomi, M. Zerbini, and M. Musiani Parvovirus B19 DNA is commonly harboured in human skin Dermatology 220 2010 138 142
5. F. Bonvicini, E. Manaresi, G. Bua, S. Venturoli, and G. Gallinella Keeping pace with parvovirus B19 genetic variability: a multiplex genotype-specific quantitative PCR assay J. Clin. Microbiol. 51 2013 3753 3759
6. F. Bonvicini, E. Manaresi, F. Di Furio, L. De Falco, and G. Gallinella Parvovirus B19 DNA CpG dinucleotide methylation and epigenetic regulation of viral expression PLoS ONE 7 2012 e33316
7. F. Bonvicini, E. Manaresi, G. Gallinella, G.A. Gentilomi, M. Musiani, and M. Zerbini Diagnosis of fetal parvovirus B19 infection: value of virological assays in fetal specimens BJOG 116 2009 813 817
8. F. Bonvicini, M. Mirasoli, E. Manaresi, G. Bua, D. Calabria, A. Roda, and G. Gallinella Single-cell chemiluminescence imaging of parvovirus B19 life cycle Virus Res. 178 2013 517 521
9. F. Bonvicini, C. Puccetti, N.C. Salfi, B. Guerra, G. Gallinella, N. Rizzo, and M. Zerbini Gestational and fetal outcomes in B19 maternal infection: a problem of diagnosis J. Clin. Microbiol. 49 2011 3514 3518
10. K.E. Brown Haematological consequences of parvovirus B19 infection Baillieres Best Pract. Res. Clin. Haematol. 13 2000 245 259
11. S.A. Bustin, V. Benes, J.A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M.W. Pfaffl, G.L. Shipley, J. Vandesompele, and C.T. Wittwer The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments Clin. Chem. 55 2009 611 622
12. H. Chisaka, E. Morita, N. Yaegashi, and K. Sugamura Parvovirus B19 and the pathogenesis of anaemia Rev. Med. Virol. 13 2003 347 359
13. Y. Crabol, B. Terrier, F. Rozenberg, V. Pestre, C. Legendre, O. Hermine, C. Montagnier-Petrissans, L. Guillevin, and L. Mouthon Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature Clin. Infect. Dis. 2012
14. E. De Clercq The acyclic nucleoside phosphonates from inception to clinical use: historical perspective Antiviral Res. 75 2007 1 13
15. E. De Clercq, and A. Holy Acyclic nucleoside phosphonates: a key class of antiviral drugs Nat. Rev. Drug Discovery 4 2005 928 940
16. T. De Schutter, G. Andrei, D. Topalis, L. Naesens, and R. Snoeck Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage BMC Med. Genomics 6 2013 18
17. A. Duechting, C. Tschope, H. Kaiser, T. Lamkemeyer, N. Tanaka, S. Aberle, F. Lang, J. Torresi, R. Kandolf, and C.T. Bock Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells J. Virol. 82 2008 7942 7952
18. M. Enders, A. Weidner, I. Zoellner, K. Searle, and G. Enders Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases Prenat. Diagn. 24 2004 513 518
19. C. Filippone, R. Franssila, A. Kumar, L. Saikko, P.E. Kovanen, M. Soderlund-Venermo, and K. Hedman Erythroid progenitor cells expanded from peripheral blood without mobilization or preselection: molecular characteristics and functional competence PLoS ONE 5 2010 e9496
20. G. Gallinella Parvovirus B19 Achievements and Challenges ISRN Virol. 2013 10.5402/2013/898730
21. G. Gallinella, E. Manaresi, E. Zuffi, S. Venturoli, L. Bonsi, G.P. Bagnara, M. Musiani, and M. Zerbini Different patterns of restriction to B19 parvovirus replication in human blast cell lines Virology 278 2000 361 367
22. J.R. Kerr Pathogenesis of human parvovirus B19 in rheumatic disease Ann. Rheum. Dis. 59 2000 672 683
23. A. King, E. Lefkowitz, M. Adams, and E. Carstens Ninth Report of the International Committee on Taxonomy of Viruses (2013 release) 2011 Elsevier
24. H.W. Lehmann, P. von Landenberg, and S. Modrow Parvovirus B19 infection and autoimmune disease Autoimmun. Rev. 2 2003 218 223
25. J. Lu, N. Zhi, S. Wong, and K.E. Brown Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein J. Infect. Dis. 193 2006 582 590
26. W.C. Magee, and D.H. Evans The antiviral activity and mechanism of action of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] (HPMP) nucleosides Antiviral Res. 96 2012 169 180
27. A. Manning, S.J. Willey, J.E. Bell, and P. Simmonds Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus J. Infect. Dis. 195 2007 1345 1352
28. S. Modrow Parvovirus B19: the causative agent of dilated cardiomyopathy or a harmless passenger of the human myocard? Ernst Schering Res. Found. Workshop 2006 63 82
29. L. Mouthon, and O. Lortholary Intravenous immunoglobulins in infectious diseases: where do we stand? Clin. Microbiol. Infect. 9 2003 333 338
30. P. Norja, K. Hokynar, L.M. Aaltonen, R. Chen, A. Ranki, E.K. Partio, O. Kiviluoto, I. Davidkin, T. Leivo, A.M. Eis-Hubinger, B. Schneider, H.P. Fischer, R. Tolba, O. Vapalahti, A. Vaheri, M. Soderlund-Venermo, and K. Hedman Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue Proc. Natl. Acad. Sci. USA 2006 7450 7453
31. C.H. Rinaldo, R. Gosert, E. Bernhoff, S. Finstad, and H.H. Hirsch 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells Antimicrob. Agents Chemother. 54 2010 4714 4722
32. S.L. Williams-Aziz, C.B. Hartline, E.A. Harden, S.L. Daily, M.N. Prichard, N.L. Kushner, J.R. Beadle, W.B. Wan, K.Y. Hostetler, and E.R. Kern Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro Antimicrob. Agents Chemother. 49 2005 3724 3733
33. S. Wong, and K.E. Brown Development of an improved method of detection of infectious parvovirus B19 J. Clin. Virol. 35 2006 407 413
34. S. Wong, N. Zhi, C. Filippone, K. Keyvanfar, S. Kajigaya, K.E. Brown, and N.S. Young Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication J. Virol. 82 2008 2470 2476
35. N.S. Young, and K.E. Brown Parvovirus B19 N. Engl. J. Med. 350 2004 586 597